Pivanex|122110-53-6|(AN-9; Pivalyloxymethyl butyrate)-陌孚医药/Medlife

您当前的位置：

Pivanex (Synonyms: AN-9; Pivalyloxymethyl butyrate)

目录号: PL02450 纯度: ≥95%

CAS No. :122110-53-6

商品编号	规格	价格	会员价
PL02450-5mg	5mg	¥494.55	请登录
PL02450-10mg	10mg	¥741.82	请登录
PL02450-25mg	25mg	¥1483.64	请登录
PL02450-50mg	50mg	¥2225.45	请登录
PL02450-100mg	100mg	¥3461.82	请登录
PL02450-200mg	200mg	询价	询价
PL02450-500mg	500mg	询价	询价
PL02450-10mM*1mLinDMSO	10mM*1mLinDMSO	¥544.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	Pivanex
中文别名	新戊酰基氧基甲基丁酸酯
英文名称	Pivanex
英文别名	Butanoic acid,(2,2-dimethyl-1-oxopropoxy)methyl ester;pivalyloxymethyl butyrate;((2,2-Dimethylpropanoyl)oxy)methyl butanoate;pivaloyloxymethyl butyrate;Pivaloyloxymethyl butyrate Pivanex;Pivanex;Pivanex(TM);Brn 4861411;Butanoic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester;AN-9;AN 9;AN 9 (ion exchanger);55VNK5440P;C10H18O4;pivaloyloxymethylbutyrate;DB05103;API0000914;butanoyloxymethyl ;Pivalyloxymethyl butyrate;Pivaloyloxymethyl butyrate
Cas No.	122110-53-6
分子式	C₁₀H₁₈O₄
分子量	202.25
包装储存	Pure form -20°C 3 years；4°C 2 years

产品详情

Pivanex (AN-9) 是丁酸的衍生物，是口服有效的 HDAC 抑制剂。Pivanex 可下调 bcr-abl 蛋白，增强凋亡 (apoptosis)。Pivanex 具有抗转移和抗血管生成的活性

生物活性

Pivanex (AN-9), a derivative of Butyric acid, is an orally active HDAC inhibitor. Pivanex down-regulates bcr-abl protein and enhances apoptosis. Pivanex has antimetastic and antiangiogenic properties.

性状

Liquid

IC50 & Target[1][2]

HDAC Bcr-Abl

体外研究(In Vitro)

Pivanex (100-500 μM) exhibits significant anti-proliferation activity in K562 cells.
Pivanex (100-500 μM) also enhances apoptosis and caspase activity in K562 cells.
Pivanex (200 μM) induces enhancement in the G2-M phase, a moderate enhancement in the S phase and a slight reduction in G0-G1 of the cell cycle.
Pivanex (AN-9) has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

Pivanex (AN9, 200 mg/kg, b.i.d, daily) significantly improves the survival of SMN7 SMA mice. Pivanex (AN9) treatment also marked delays the end stage of disease as defined by the onset of body mass loss. has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Pure form -20°C 3 years；4°C 2 years

ClinicalTrial

参考文献

[1]. Rabizadeh E, et al. Pivanex, a histone deacetylase inhibitor, induces changes in BCR-ABL expression and when combined with STI571, acts synergistically in a chronic myelocytic leukemia cell line. Leuk Res. 2007 Aug;31(8):1115-23. Epub 2007 Jan 30.
[2]. Batova A, et al. The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines. Blood. 2002 Nov 1;100(9):3319-24.

溶解度数据	In Vitro: DMSO : ≥ 100 mg/mL (494.44 mM)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation